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Introduction
Variant calling from next generation sequencing (NGS) data 
is a highly active area of bioinformatics, important to many 
clinical, commercial and academic applications. Several open-
source tools are available and have been integrated into variant 
calling pipelines by many laboratories1–6. Commercial solu-
tions and/or in-house proprietary tools are also increasingly 
being used by NGS analysis providers. Evaluations of pipeline 
performance are often based on internal data. This makes 
comparison, standardisation and regulation of NGS variant calling 
performance difficult7.
Assessment of variant calling performance is vital for improve-
ment and optimisation of NGS variant calling. Comparative 
performance across pipelines is also of increasing impor-
tance, as the number of different analysis tools and providers 
continues to expand. The availability of benchmarking 
datasets with orthogonally confirmed positive and negative sites 
are required for optimal independent assessment of sensitivity, 
specificity and false detection rates (FDR). 
We previously made available the ICR142 NGS validation 
series that includes NGS and Sanger data from 142 samples8. To 
construct the ICR142 NGS validation series we analysed exome 
sequence data from the 142 samples with multiple variant 
callers and undertook Sanger sequencing analysis at 704 sites 
to generate a dataset useful for systematic, transparent variant 
calling assessment and comparison8.
Here we present ICR142 Benchmarker9, a tool to generate out-
puts for assessing variant calling performance using the ICR142 
NGS validation series. We used ICR142 Benchmarker with 
VCF files from GATK, OpEx and DeepVariant to provide 
guidance on expected variant caller performance compared 
to three open-source pipelines1,10,11. We then used ICR142 
Benchmarker with VCF files from two commercial NGS variant 
calling providers, to provide comparison data to facilitate 
optimisation of their in-house pipelines, and to help give 
transparency of performance for their customers.
Methods
ICR142 NGS validation series
The ICR142 NGS validation series is a dataset that includes high-
quality exome sequence data from 142 samples together with 
Sanger sequence data at 704 sites; 416 sites with variants and 
288 sites at which variants were called by a variant caller, but no 
variant is present in the corresponding Sanger sequence. The 
exome sequence data was generated using the Illumina TruSeq 
Exome and a HiSeq2000 sequencer. Full details of the ICR142 
series are given in Ruark et al.8. In total, the ICR142 NGS 
validation series includes 704 sites, comprised of 123 base 
substitution variants, 293 insertions and/or deletion (indel) 
variants, 41 negative base substitution sites and 247 negative 
indel sites (Figure 1)8.
To determine if a variant was present we examined each Sanger 
sequence with Chromas software v2.13. For each site we selected 
an ENST from release 65 as the reference sequence. We analysed 
a region of interest of at least 100 base pairs (bp) of sequence 
flanking each variant site to allow for position/annotation errors.
We considered a base substitution to be confirmed if the 
correct variant was called at the exact position and the variant 
base signal was accompanied by a corresponding reduction in 
the reference base signal. We considered an indel variant to be 
confirmed if an indel variant was present in the region of 
interest and the indel variant allele signal was present along 
the complete length of the region of interest.
We considered a site negative for a base substitution if the 
exact base substitution was not present. We considered a site 
negative for an indel if no indel was detected in the 200bp region 
of interest.
ICR142 Benchmarker
Implementation. ICR142 Benchmarker9 is implemented as 
an easy-to-use tool for assessing variant calling performance 
using the ICR142 NGS validation series. It can be used with 
hg19/GRCh37 or hg38/GRCh38 data. The tool includes an 
analysis script and three supporting files: the Sanger data file, 
the Report template file and the descriptive ColumnHeadings.
txt file. ICR142 Benchmarker provides a series of informative 
metrics with increasing levels of detail from overall calling 
performance to per site profiles together with a one page report 
summarising both standalone performance and comparative 
performance against widely-used open-source pipelines. ICR142 
Benchmarker is implemented in R and is publically available 
at https://github.com/RahmanTeamDevelopment/ICR142_Bench-
marker/releases.
ICR142 Benchmarker requires an input file containing the 
paths to VCF version 4.X files. The VCF files must each rep-
resent a single sample. The script expects the ALT column to 
contain only one call. Any base substitution calls are expected 
to have REF and ALT values of length one, e.g. REF / ALT of 
GTCA / ATCA should be trimmed to G / A. Multi-sample VCF or 
gVCF files should be parsed to fulfil the above criteria.
At each site, ICR142 Benchmarker assesses both variant 
detection and accuracy of variant representation, with missing 
genotypes allowed. Base substitution variants are both detected 
and accurately represented if the correct variant is called at 
            Amendments from Version 1
We have updated ICR142 Benchmarker so that it can now be 
used with hg19/GRCh37 or hg38/GRCh38 data. We have also 
made other minor changes to the paper to enhance clarity 
following helpful comments from the reviewers. This includes a 
slight change to the title to include the word ‘performance’. 
See referee reports
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the exact position. If an incorrect base substitution is called at 
that position it is considered a missed variant. For negative base 
substitution sites a false positive base substitution call is 
assigned if any base substitution call is made at the exact 
position. Due to the more complex nature of indel detection and 
representation, a stringent exact matching approach is not appro-
priate. We thus report indel detection as the number of indel 
calls within a 200bp window centred on the site position, for 
both true indel and negative indel sites. An indel variant is 
considered to be both detected and accurately represented if 
an exact match is found. For negative indel sites a false indel 
call is assigned if the indel detection value is greater than 0. 
Summary metrics are calculated from the detection values. Any 
missing values are treated as ‘no call’ in the metric calculations.
ICR142 Benchmarker generates five output files, four tab-sepa-
rated .txt files and one Word document .docx. The Summary.txt 
file provides summary performance metrics for the evaluated 
method, specifically the overall sensitivity, specificity and 
false detection rate (FDR) values. These three metrics are also 
separately calculated for base substitutions or indels. The 
FullResults.txt file contains all of the Sanger validation 
information from the ICR142 dataset and information on site- 
specific performance at each of the 704 sites. The FalsePositives.
txt and TruePositives.txt files contain the relevant lines of the 
input VCF files for false positive and true positive variant calls, 
respectively. Detailed description of all columns in the .txt files 
is provided in the ColumnHeaders.txt supporting file.
The Report.docx file provides a summary variant calling analysis 
report of performance using the ICR142 dataset. This single 
page document is directly constructed from the Summary.
txt and FullResults.txt files and thus is transparent and repro-
ducible. Key points from the detailed outputs are highlighted 
to the user, including information about performance compared 
to widely-used open-source variant callers.
Operation. ICR142 Benchmarker can be installed by running 
a simple Bash script. Installation requires R version 3.1.2 or 
later and a capacity to build packages from source. ICR142 
Benchmarker implements full version control using packrat12. 
This approach ensures ICR142 Benchmarker implementation 
will not be affected by future changes of incorporated packages 
or their dependencies. Once installed, the tool can be run 
from a Linux/Unix command line. The ICR142 Benchmarker 
documentation is available at GitHub: https://github.com/Rahman-
TeamDevelopment/ICR142_Benchmarker/.
Assessing variant calling performance
To evaluate the utility of the ICR142 NGS validation series and 
ICR142 Benchmarker we analysed data from three different 
open-source variant callers, GATK, OpEx and DeepVariant1,10,11 
and two commercial variant callers from Company A and 
Company B.
To generate BAM files for the GATK analysis, we aligned the 
ICR142 FASTQ files with BWA-MEM v0.7.12 and removed 
Figure 1. Layout of the 704 Sanger validated variant sites. Breakdown of the 704 Sanger validated base substitutions, insertion and/or 
deletions (indels), and negative sites from 142 samples. The diagram shows the exact number of base substitutions, deletions, insertions, 
complex indels, and sites without a base substitution or indel.
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duplicates using Picard v1.12913. We ran a GATK v3.4-46 
analysis on the 142 BAM files to create a multi-sample VCF file 
(Supplementary File 1). We then applied standard additional filters 
of AB > 0.2, DP ≥ 10 and GQ ≥ 20 and included the remaining 
variants as the GATK set.
We ran OpEx v1.0.0, which uses Platypus v0.1.5 as its variant 
caller, with default settings to generate 142 single sample 
VCF output files from the ICR142 FASTQ files11. Variants 
flagged as “high” by OpEx were included as the OpEx set.
We ran DeepVariant10 with default settings using the OpEx 
BAM files to generate 142 gVCF output files. Two versions of 
DeepVariant were run; v0.5.2 and v0.6.1.
Two commercial variant calling providers, referred to as 
Company A and Company B, supplied data for the ICR142 
validation series, Company A supplied 142 individual VCF files 
and Company B supplied a multi-sample gVCF file.
We pre-processed all multi-sample and gVCF files to ensure 
compatibility with the script. Multi-sample files were split 
into 142 single sample files with the vcf-subset command in 
vcftools v0.1.1414. For each gVCF file, we analysed the vari-
ant call subset to generate an initial result for each site. The 
reference call subset was then used to assign a missing value at 
sites with no call.
Results
Variant detection performance
We used the data from GATK, OpEx and DeepVariant v0.6.1 
to provide a baseline for expected variant calling performance 
(Table 1 and Supplementary File 2). Comparison of the three 
pipelines showed concordance at 92% of sites, both positive 
and negative. Because the same alignment files were used 
for both OpEx and DeepVariant (BWA), with a related but 
different aligner used for GATK (BWA-MEM), one might have 
expected the OpEx and DeepVariant results to be more similar 
to one another than to GATK. However, the aligner used did 
not seem to have a strong impact, as GATK and DeepVariant 
showed similar performance, while OpEx had a better false 
detection rate but lower sensitivity. This was expected, as the 
OpEx “high” quality filter was designed to achieve exactly this 
balance for its first-pass exome sequence analysis11. 
Sites where all three pipelines called false positives highlight 
common challenges in variant calling. False positive base sub-
stitutions in POTEH and CHEK2 are likely due to non-specific 
capture of sequences derived from homologous genomic 
sequences. For example, the region surrounding the false 
positive position on chromosome 22 in POTEH has 90–95% 
homology with other paralogs of the POTE gene, with the 
allele at the exact position varying between them. False positive 
indels called in MUC13 and SLC39A14 provide examples of 
the challenges of variant calling in short repeating sequence 
motifs in NGS data. Although it is possible that the Sanger result 
is a false negative at these sites, we consider this to be unlikely.
The discordant false positive values reveal pipeline-specific 
differences in variant calling performance. GATK had seven 
unique sites with false positives, i.e. not called by either OpEx 
or DeepVariant, all of which were indels. These included two 
sites with a long insertion (SiteIDs 31, 290) and one site with a 
cluster of multiple calls (SiteID 75) (Supplementary File 2). 
Within the cluster, there would be no overall change in length 
if one could assume that all calls occurred on the same allele. 
However, phasing information was not provided by GATK until 
v3.3, and is only run automatically under specific conditions in 
more recent versions. Users of GATK should be cautious when 
multiple indels are called in close proximity in the same sam-
ple and consider visual inspection of the BAM file to check 
phasing, if phasing was not performed automatically. DeepVariant 
Table 1. Performance of multiple variant callers based on the ICR142 dataset. Performance 
metrics were calculated as: Sensitivity = TP/(TP+FN), Specificity = TN/(TN+FP) or False 
detection rate = FP/(FP+TP), where TP = true positive sites; TN = true negative sites; FP = false 
positive sites; FN = false negative sites as described in Methods. The ICR142 dataset was 






Overall 404/416 (97%) 391/416 (94%) 405/416 (97%)
Base substitutions 123/123 (100%) 118/123 (96%) 123/123 (100%)
Indels 281/293 (96%) 273/293 (93%) 282/293 (96%)
Specificity
Overall 266/288 (92%) 279/288 (97%) 270/288 (94%)
Base substitutions 39/41 (95%) 39/41 (95%) 35/41 (85%)
Indels 227/247 (92%) 240/247 (97%) 235/247 (95%)
False detection rate
Overall 22/426 (5%) 9/400 (2%) 18/423 (4%)
Base substitutions 2/125 (2%) 2/120 (2%) 6/129 (5%)
Indels 20/301 (7%) 7/280 (2%) 12/294 (4%)
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had four unique sites with false positives, all of which were 
base substitutions with QUAL value ranging from 9.3–20.315. 
OpEx did not have any unique sites with false positives, 
consistent with the priority of the high quality OpEx filter 
to limit the false detection rate.
Indel detection and representation accuracy
ICR142 Benchmarker makes a distinction between variant detec-
tion and accurate variant representation since indels detected 
by NGS are often validated by an orthogonal technique such 
as Sanger sequencing, and the call amended if required. There 
were ten variants which were detected by all three pipelines but 
not correctly represented by at least one pipeline. Nine vari-
ants were incorrectly represented by all three pipelines. These 
were all complex indels, indicating the need for improvement 
or further standardisation in the representation of this impor-
tant class of variant. The final variant, an inframe deletion of 
24bp in GPRIN1 (SiteID 607), was correctly represented by 
OpEx but both GATK and DeepVariant represented this variant 
as two separate frameshifting deletions of 13bp and 11bp. This 
is a crucial difference, as the functional impact of inframe and 
frameshifting variants is often markedly different. Excluding 
complex indels, all three methods had greater than 98% accu-
racy, only OpEx achieved 100% accuracy, with all of the 
264 detected insertions or deletions correctly represented.
Utility in variant calling regression testing
Variant calling pipelines are frequently updated. Regression 
testing ensures previously developed and tested pipelines still 
perform in the same way after updates have been implemented. 
The ICR142 NGS validation series allows independent regres-
sion testing, and we believe it could be usefully incorporated 
into variant calling development processes, particularly in the 
clinical setting.
To investigate this we performed regression testing by per-
forming the same ICR142 Benchmarker analysis with 
DeepVariant v0.5.2 and v0.6.1. We found that v0.6.1 improved 
on v0.5.2 across all metrics, for both base substitutions and 
indels15. Comparison of the site-specific performance allowed 
us to draw more detailed insights. There were ten sites with a 
change in performance (Supplementary File 3). For two sites 
(SiteID 34, 666) with a single correctly detected indel, v0.6.1 
detected an additional indel, an unexpected change in indel 
calling behaviour. For seven sites the calling performance 
improved, with one false positive base substitution and two 
false positive indels no longer called and four previously unde-
tected indel variants now called by v0.6.1. However, one site 
had decreased performance, with three false positive indels 
newly called by v0.6.1 at a site in PABPC3 (SiteID 114). As 
one of the four newly detected indel variants occurred at a 
nearby site in PABPC3 in a different sample, this indicates 
that the improved calling performance comes at the cost of 
additional false positives at one site. Taken together, these 
data indicate that v0.6.1 provides validated improvement on 
v0.5.2, with some caveats that may inform future updates.
Utility in creation of variant detection filters
Many variant callers apply filters of the raw calls to improve 
performance. We believe the ICR142 validation series and ICR142 
Benchmarker can be used to inform optimal filter creation. 
To evaluate this we investigated the performance of DeepVariant 
v0.6.1. We found that while sensitivity was excellent for 
both base substitutions and indels, specificity was surprisingly 
low for base substitutions at 85% (Table 1). We looked at the 
quality information returned by DeepVariant for all base sub-
stitution positive and negative sites in the ICR142 series15. We 
found that imposing a threshold of 30 on the QUAL column 
for base substitution calls reduced the false detection rate from 
5% to 2%, increased the specificity to 95%, and did not greatly 
reduce the sensitivity, as only one variant was excluded, which 
had a QUAL value of 29.3, resulting in a sensitivity of 99%. 
We thus recommend using a filter of QUAL threshold of 30 for 
base substitution calls when using DeepVariant v0.6.1.
Benchmarking variant detection performance
Using the concordant data from the open-source pipelines 
allowed us to describe the expected baseline performance 
for variant calling (Table 2 and Supplementary File 2). There 
were 387 variants detected by GATK, OpEx and DeepVariant, 
which we call Group A variants. Any method seeking to per-
form as well as these open-source pipelines should be able to 
detect all variants in Group A. There were 261 sites where 
no variant was detected, which we call Group B. Methods 
aiming to have equivalent performance to open-source pipelines 
should avoid making variant calls at all Group B sites. Failure 
to detect a Group A variant or calling a variant at a Group B 
site indicates substandard performance and warrants further 
investigation at the algorithmic and/or filtering stage.
To demonstrate the utility of ICR142 Benchmarker to provide 
useful comparative performance information, we assessed vari-
ant calling by two commercial pipelines, which we call Company 
A and Company B (Supplementary File 4 and Supplementary 
File 5).
Table 2. Expected baseline performance for 
variant calling. Group A – variants that should 
be detected by any variant calling pipeline; 
Group B – sites in which a base substitution or 
insertion and/or deletion should not be called.
Number of Sites
Group A 
- Base substitution variants 118
- Deletion variants 186
- Insertion variants 74
- Complex indel variants 9
Group B 
- No base substitution 35
- No indel 226
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Company A showed overall good sensitivity (96%), spe-
cificity (95%) and false detection rate (4%) (Supplementary 
File 4). However, six Group A variants were not called and a 
false positive was called at one Group B site. The lower than 
typical ability to detect Group A variants indicates further 
work should be performed to understand why these variants were 
missed.
Company B also showed overall good sensitivity (98%), spe-
cificity (94%) and false detection rate (4%) (Supplementary 
File 5). However, one Group A variant was not called and false 
positives were called at three Group B sites. Deeper evalua-
tion of these results by the companies could help them improve 
their variant calling performance.
The ICR142 Benchmarker report for each company provides 
a clear summary of performance overall and for indels and base 
substitutions separately. The report also gives specific bench-
marking information about Group A variants and Group B sites 
in a simple, clear and concise fashion (Supplementary File 4 and 
Supplementary File 5). The report further highlights if missing 
data prevents assessment at any given site, as was the case for one 
negative site in the data from Company B (Supplementary File 5).
Conclusion
Evaluation, optimisation and benchmarking of performance, 
including comparison with current widely-used pipelines, is essen-
tial for clinical, commercial and academic NGS variant calling 
applications. We have developed a tool, ICR142 Benchmarker, 
to achieve these essential requirements in a consistent, reproduc-
ible and transparent fashion, using the ICR142 NGS validation 
dataset. ICR142 Benchmarker returns useful outputs with 
various levels of detail to allow both broad and deep under-
standing of variant calling performance. ICR142 Benchmarker 
can be applied to VCF files generated by any variant caller, 
allowing intra- and inter-pipeline comparison. ICR142 
Benchmarker is also useful in the optimisation of variant 
calling algorithms and outputs, including regression testing 
and filter creation. The ICR142 Benchmarker report provides 
simple, clear and concise summary statements about a pipe-
line’s performance, including comparison with the performance 
of widely-used open-source pipelines. Use of the ICR142 
NGS validation series and ICR142 Benchmarker can therefore 
facilitate in-house optimisation and direct comparison of variant 
calling methods for NGS data.
Data availability
The FASTQ files for the ICR142 validation series are avail-
able from the European Genome-phenome archive (EGA). The 
accession number is EGAS00001001332.
Software availability
ICR142 Benchmarker is available at: https://github.com/Rahman-
TeamDevelopment/ICR142_Benchmarker/releases
Latest source code: https://github.com/RahmanTeamDevelopment/
ICR142_Benchmarker
Archived source code as at time of publication: http://doi.
org/10.5281/zenodo.14690139 
Software license: MIT
The full ICR142 Benchmarker documentation is given in 
Supplementary File 6 and is available at: https://github.com/ 
RahmanTeamDevelopment/ICR142_Benchmarker/
Supporting data files of GATK, OpEx, DeepVariant v0.5.2 
and v0.6.1 input and output files have been archived as a single 
project file on Open Science Framework: http://doi.org/10.17605/
OSF.IO/H3ZR915 under a CC0 1.0 Universal licence.
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Supplementary material
Supplementary File 1. GATK analysis commands
Click here to access the data
Supplementary File 2. Site-specific ICR142 Benchmarker results for GATK, OpEx and DeepVariant
Click here to access the data
The description of the column headings are given below:
Sample – sample name in the ICR142 NGS validation series
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Gene – HGNC symbol
SangerCall – the most 3’ representation annotated with CSN v1.016 or “No” if no variant present
Type – “bs”, “del”, “ins”, “complex”, or “indel” for base substitutions, simple deletions, simple insertions, complex indels, or negative indel 
sites, respectively
Transcript – the ENST ID from Ensembl v65 used to annotate the Sanger call
CHR – chromosome
EvaluatedPosition - evaluated hg19 site position, centre of designed amplicon
POS – the left-aligned position in hg19 coordinates for variants or “.” if no variant present
REF – the reference allele in hg19 for variants or “.” if no variant present
ALT – the alternate allele for variants or “.” if no variant present
SiteID – site ID in the ICR142 NGS validation series
Zygosity – “heterozygous” a variant that is present on only one allele or “homozygous” a variant that is present on both alleles
OpEx – “.” if there is a missing genotype, 0 if site is not called by OpEx, 1 if a base substitution is called when Type = “bs”, or integer value 
X if X indels are called when Type = “del”, “ins”, “complex”, or “indel”
OpExExactFinalMatch – “yes” if CHR, POS, REF and ALT all match when SangerCall is not “No” and OpEx > 0, “no” if CHR, POS REF 
and ALT do not match when SangerCall is not “No” and OpEx > 0 , “.” otherwise
GATK – “.” if there is a missing genotype, 0 if site is not called by GATK, 1 if a base substitution is called when Type = “bs”, or integer 
value X if X indels are called when Type = “del”, “ins”, “complex”, or “indel”
GATKExactFinalMatch – “yes” if CHR, POS, REF and ALT all match when SangerCall is not “No” and GATK > 0, “no” if CHR, POS 
REF and ALT do not match when SangerCall is not “No” and GATK > 0 , “.” otherwise
DeepVariant – “.” if there is a missing genotype, 0 if site is not called by DeepVariant, 1 if a base substitution is called when Type = “bs”, 
or integer value X if X indels are called when Type = “del”, “ins”, “complex”, or “indel”
DeepVariantExactFinalMatch – “yes” if CHR, POS, REF and ALT all match when SangerCall is not “No” and DeepVariant > 0, “no” if 
CHR, POS REF and ALT do not match when SangerCall is not “No” and DeepVariant > 0 , “.” otherwise
Group – “A” if SangerCall is not “No” and GATK, OpEx and DeepVariant are all > 0 , “B” if SangerCall is “No” and GATK, OpEx and 
DeepVariant are all 0, “.” otherwise
Supplementary File 3. Variant calling regression testing of DeepVariant v0.5.2 and v0.6.1
Click here to access the data
The description of the column headings are given below:
Sample– sample name in the ICR142 NGS validation series
Gene– HGNC symbol
SangerCall – the most 3’ representation annotated with CSN v1.016 or “No” if no variant present
Type– “bs”, “del”, “ins”, “complex”, or “indel” for base substitutions, simple deletions, simple insertions, complex indels, or negative indel 
sites, respectively
Transcript – the ENST ID from Ensembl v65 used to annotate the Sanger call
CHR – chromosome
EvaluatedPosition - evaluated hg19 site position, centre of designed amplicon
POS – the left-aligned position in hg19 coordinates for variants or “.” if no variant present
REF – the reference allele in hg19 for variants or “.” if no variant present
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ALT – the alternate allele for variants or “.” if no variant present
SiteID – site ID in the ICR142 NGS validation series
Group – “A” if SangerCall is not “No” and GATK, OpEx and DeepVariant are all > 0 , “B” if SangerCall is “No” and GATK, OpEx and 
DeepVariant are all 0, “.” Otherwise
DeepVariant v0.5.2 – “.” if there is a missing genotype, 0 if site is not called by DeepVariant v0.5.2, 1 if a base substitution is called when 
Type = “bs”, or integer value X if X indels are called when Type = “del”, “ins”, “complex”, or “indel”
DeepVariant v0.6.1 – “.” if there is a missing genotype, 0 if site is not called by DeepVariant v0.6.1, 1 if a base substitution is called when 
Type = “bs”, or integer value X if X indels are called when Type = “del”, “ins”, “complex”, or “indel”
ConcordantFinalResult v0.5.2 – “no“ if either SangerCall is “No“ and DeepVariant v0.5.2 is >0 or SangerCall is not “No“ and DeepVari-
ant v0.5.2 is “0“ or “.“, “yes“ if SangerCall and DeepVariant v0.5.2 are concordant
ConcordantFinalResult v0.6.1 – “no“ if either SangerCall is “No“ and DeepVariant v0.6.1 is >0 or SangerCall is not “No“ and DeepVari-
ant v0.6.1 is “0“ or “.“, “yes“ if SangerCall and DeepVariant v0.6.1 are concordant
ExactFinalMatch v0.5.2 – “yes” if CHR, POS, REF and ALT all match when SangerCall is not “No” and DeepVariant v0.5.2 > 0, “no” if 
CHR, POS REF and ALT do not match when SangerCall is not “No” and DeepVariant v0.5.2 > 0 , “.” otherwise
ExactFinalMatch v0.6.1 – “yes” if CHR, POS, REF and ALT all match when SangerCall is not “No” and DeepVariant v0.6.1 > 0, “no” if 
CHR, POS REF and ALT do not match when SangerCall is not “No” and DeepVariant v0.6.1 > 0 , “.” otherwise
Supplementary File 4. ICR142 Benchmarker Report for Company A.
Click here to access the data
Supplementary File 5. ICR142 Benchmarker Report for Company B.
Click here to access the data
Supplementary File 6. ICR142 Benchmarker v1.0.1 documentation.
Click here to access the data
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